2 the gastrointestinal tract yet described (2) . inducing acute mucosal injury in the stomach and small intestine (2, 3) . GonzalezCrussi and Hsueh (4) have previously reported a model of NEC produced in the rat by injecting PAF and lipopolysaccharide into the descending aorta. These investigators have also reported that the PAF concentration in plasma was elevated and that the activity of PAF-AH was significantly lower in patients with NEC (5) .
The importance of PAF-AH in the regulation of the PAF concentration in a number of conditions has recently been emphasized (6) . The plasma activity of this enzyme has been shown to increase during the "stress" reaction of the lizard (7) . in patients with ischemic cerebrovascular disease (8) , with insulin-dependent diabetes mellitus (9) , in spontaneous hypertensive rats (lo), and in Caucasian males with hypertension (1). The plasma activity is decreased in asthmatic children (1 I ) and in the maternal plasma during the latter stages of pregnancy (12) . Furthermore, it has been shown that the activity of the plasma isozyme of PAF-AH is regulated by various steroid hormones in vivo (1 3, 14) and in different cell types (6, 15) . Recently, we have reported that PAF-AH is present in human milk (16) . The enzyme is the isozyme of the plasma type and is resistant to exposure to low pH and proteolysis. This observation suggests that the PAF-AH of human milk may be important in the prevention of PAF accumulation in the small intestinal mucosa. In the present investigation, we have further developed a rat model of NEC by injection of PAF and examined the role of PAF-AH on this disease.
MATERIALS AND METHODS
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vein into heparinized capillary tubes on d 1 (before the hormone injection). The plasma was isolated by centrifugation at 600 x g for 5 min, hematocrit was measured, and the plasma stored at -20°C before assay. The 4th sample was obtained 24 h after the final injection. In some cases, samples were also obtained on d 7 and 14.
4-APP treatment. 4 -APP was administered intraperitoneally for 3 d at a dose of 2 mg/100 g body weight. The 4-APP was dissolved in normal saline and prepared fresh just before use. Food. but not water, was withheld from the 4-APP-and vehicletreated animals.
Assa.vs. Surgical preparation. The model used to produce the NEClike disease is similar to that previously described by GonzalezCrussi and Hsueh (4) . Either male or female Wistar rats, 200 + 20 g, were used in all experiments. The rats were anesthetized with pentobarbital sodium (40 mg/kg), the abdomen was incised along the midline, and various amounts of PAF, dissolved in 0.25% BSA in 0.9% saline, were injected into the abdominal aorta at the level of the renal arteries. The final injection volume was 0.2 mL. After injection, the abdomen was closed, and the animals were killed within 2 h after injection. When up to 2 pg of PAF was injected through the tail vein. no necrosis was observed. The entire small intestine was removed. the intestinal contents were gently washed out with cold saline. and sections (upper, middle, and lower) of tissue were fixed in alcoholic formalin. The tissues were stained with hematoxylin and eosin. Blood samples were collected before and after injection for determination of PAF-AH activity and hematocrit.
RESULTS
Gross and micro.scopic description.
The entire small bowel of the rats was removed from the ligament of Treitz to the cecum. The serosa and mucosa were unremarkable (Fig. IA, panel I ) .
In the PAF-treated rats, the serosal surface was diffusely discolored and hemorrhagic (Fig. IA, panel 2) . On opening the bowel. lumen and mucosa were also diffusely hemorrhagic and necrotic. Microscopically, the vehicle-treated rats demonstrated normal villous architecture and a normal population of cells within the lamina propria ( Fig. 1 B, panc~l I ) . The PAF-treated rats demonstrated diffuse full-thickness necrosis and hemorrhage of the mucosa ( Fig. I B, panel 2) .
Dose-dependent administration o f P,4E
The results of our observations are summarized in Table 1 ; various amounts of PAF were administered for different time periods. As shown in Table I . PAF at a dose of 0.35 pg was sufficient to cause bowel necrosis. whereas PAF at doses of 0.25 pg or lower was ineffective in causing bowel necrosis as judged by gross examination. These observations were confirmed by histologic examination. The histologic examination of sections of the duodenum. jejunum, and ileum revealcd tissue pathology that was identical to that seen in patients with NEC. A significant number of animals developed the disease within I h if a high conccntration of PAF was injected (greater than I pg). When 2 pg of PAF was administered via the tail vein. no bowel necrosis was observed at the end of a 2-h period. When as little as 0.35 pg of PAF was administered into the mesenteric artery, the gross and microscopic finding of the necrosis could be detected within 15 min.
E[/i>ct r!f'desamrthasonc~ on pla.sma PAF-AH activity and NEC development. Previously, we have reported that dexamethasone injection increased the plasma PAF-AH activity in adult male and female rats ( 13. 14). When dexamethasone was administered, the activity returned to normal levels within 7 d. In the reported experiments (Table 2) . the plasma activity in rats treated with dexamethasone increased from 55.2 + 7.1 nmol x min-' x mL-' plasma on d 1 to 117.5 f 7.9 nmol x min-I X mL-' plasma by d 4. When 0.35 pg of PAF was injected into the abdominal aorta of dexamethasone-treated rats on d 4. the gross and microscopic finding illustrated in Figure IA and B. panel 3, was observed. As can be seen, the serosa and mucosa of the small intestine were normal upon both gross and microscopic examination. As was previously shown, this concentration of PAF causes a marked necrosis in untreated rats. It thus appears that the administration of dexamethasone completely protected the animals from the necrosis.
E0i~c.t c~frnc~dros~proge~.~tc~rone, estrogen, and 4-'4 PP on plasma PAF-AH acrivitjv. Results similar to those obtained with dexamethasone were observed when PAF was administered to the medroxyprogesterone-treated rats on d 4. as judged by both the gross and histologic findings. The PAF-AH activity of the medroxyprogesterone-treated animals increased from 52.0 f 4.9 nmol x min-' x mL-' on d I to 83.5 + 2.7 on d 4. In contrast to the dexamethasone-treated animals. the PAF-AH activity of the medroxyprogesterone-treated group remains elevated for up to 21 d (14) . The PAF-AH activity of medroxyprogesterone treated group was 80.4 0.6 nmol x min-I x mL-' on d 14.
No necrosis was observed when PAF was administered to these animals on d 14. When 17n-ethynylestradiol was injected, the plasma PAF-AH activity decreased from 50.7 + 9.9 nmol X min-' x mL-' on d I to 3.3 + 1.1 by d 4. When these animals received injections of PAF on d 4. it was found that as little as 0.25 pg of PAF was sufficient to cause bowel necrosis and hemoconcentration.
4-APP has been used to lower the plasma lipoprotein concentration of the rat (17) . The plasma PAF-AH activity in the rat and other species is associated with the lipoproteins (6) . We had previously demonstrated that the administration of 4-APP to adult rats causes a decrease in the plasma PAF-AH (Yasuda K. Johnston JM, unpublished observations). We therefore used 4-APP to lower the plasma PAF-AH and determine its effect on the development of NEC. The PAF-AH activity of the 4-APPtreated animals was decreased from 50.9 k 3.3 nmol x min-' x mL-I on d I to 5.4 + 3.9 on d 4. It was found that as little as 0.175 pg of PAF was sufficient to cause bowel necrosis and hemoconcentration in these animals. The effects of the various treatments on the plasma PAF-AH at the end of 2 h are summarized in Table 2 . The administration of PAF caused a profound hemoconcentration due to increased vascular permeability (18) .
DISCUSSION
In the present investigation, we have further established the role of PAF in NEC. In this study, PAF was the sole autocoid administered. The observation that manipulation of the activity of the enzyme responsible for PAF inactivation affected the severity of the intestinal necrosis and hemoconcentration provides further evidence for the involvement of this potent autocoid. Wallace and Whittle (18) reported that there was a highly significant correlation between gastric damage score and degree of hemoconcentration due to plasma exudation in PAF-induced gastric mucosal necrosis. We have demonstrated a similar relationship in the NEC model in that treatment with either dexa- MacNaughton (20) reported that the damage in the small intest Two rats killed within 1 h failed to manifest necrosis. tine induced by PAF infusion was accompanied by an increase methasone or medroxyprogesterone prevented both the hemo-in the tissue formation of leukotriene B4 in the duodenum. concentration and the intestinal damage induced by PAF. Fur-jejunum, and ileum. In that study, dexamethasone pretreatment thermore, the requirement of a decreased PAF amount to cause for 36 h reduced PAF-induced intestinal damage and leukotriene NEC in animals with an extremely low PAF-AH activity further B. 4 formation, whereas gastric damage scores were not affected. supports the hypothesis of the importance of PAF in the devel-It is well established that the formation of PAF and eicosanoids opment of this disease.
are closely related ( I) . The effect of glucocorticoids on decreasing Table 2 . 
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FURUKAW eicosanoid synthesis is well established. We have suggested a role for glucocorticoids in decreasing PAF via the increase in the plasma PAF-AH activity (13, 14) . The beneficial effect of glucocorticoids in the prevention of NEC is most probably due to the effect of this hormone on the plasma activity of PAF-AH and not its direct effect on the intestine, inasmuch as medroxyprogesterone has a similar protective effect on the development of NEC and on the stimulation of the plasma PAF-AH activity. This was true for medroxyprogesterone even after 14 d, when the PAF-AH activity was still elevated and a protective effect was observed. On the other hand, estrogen causes a decrease in the plasma PAF-AH activity and these animals are sensitive to lower concentrations of PAF. Similarly, the administration of a nonsteroidal agent, 4-APP, that is known to decrease the plasma PAF-AH activity also causes an increased sensitivity to PAF and the development of NEC.
Corticosteroids are widely used clinically in the treatment of inflammation, and they have been reported to decrease the mortality associated with endotoxin-induced shock (2 1). Interestingly. Halac er 01. (22) recently demonstrated that prenatal corticosteroid therapy reduced the incidence of neonatal necrotizing enterocolitis. On the basis of the reported findings, it is suggested that one of the mechanisms involved in decreasing the incidence of NEC in the glucocorticoid-treated infants is the increase in the plasma PAF-AH activity of the treated group. The activity of PAF-AH in newborns. both animals and humans. is low at birth and increases rapidly postpartum (12. 23) . The activity increases during the first week of life. This finding adds further support to the concept that PAF-AH may play an important role in the prevention of NEC and may explain why premature infants are more susceptible to NEC development.
The beneficial effect of breast feeding in preventing the development of NEC in human neonates has been reported by several groups (24, 25) . Recently, we demonstrated that PAF-AH is present in human milk and that the enzyme is the plasma type isozyme (16) . The milk enzyme is secreted by the milk macrophages and is resistant to exposure to a low pH and proteolysis. This evidence may also be important in the prevention of PAF accumulation in the small intestine because the enzyme would escape inactivation at the pH found in the stomach of the neonate and the protease activity in the intestine. PAF-AH has been found in the milk obtained from rat, pig, goat, or human at any postpartum period. A higher activity was found in the colostrum of the pig (16) . Surprisingly little, if any, PAF-AH activity was found in bovine colostrum or milk obtained at any time postpartum (16) . It has been reported that increased PAF is present in the stools of newborns with an inflammatory bowel disease (26). The beneficial effects of breast feeding on the prevention of NEC are diminished upon pasteurization (27) . removal of the white cells (28) . or substitution with cow's milk (29). These observations are consistent with the view that one of the beneficial effects of breast feeding may be the presence of PAF-AH in the human milk. Because PAF-AH is inactivated by heat treatment, decreased amounts would be produced after freezing or white cell removal due to macrophage destruction or loss. Bovine milk could not substitute milk of other species because it does not contain significant activity of PAF-AH.
The mechanism by which an increase in the plasma PAF-AH can serve a protective function in the prevention of experimental NEC caused by PAF infusion is apparent. In contrast, the explanation as to how the PAF-AH in milk may protect against the development of NEC is less clear. A possible mechanism may reside in the fact that in both animals and humans intact proteins are known to transverse the intestinal tract in newborns (30) . This is especially true in preterm neonates. in which the permeability to macromolecules is significant (3 1. 32) . Thus. the PAF-AH of milk may penetrate the intestinal epithelium and act as a protective agent by inactivating the potent proinflammatory agent, PAF.
Increase in PAF in the small bowel in patients with NEC may be due, in part, to the inflammatory reaction to a bacterial infection. A Klebsiela species has been implicated in the development of this disease. This organism in combination with partial asphyxia was shown to produce NEC in newborn rats (33) . This group also demonstrated that the incidence of NEC was reduced when newborn rats were fed fresh breast milk compared with synthetic formulas. The pathogenesis of NEC may require the action of several factors, including proinflammatory mediators and bacterial products. It is clear, however, that PAF may play an important role in the pathogenesis of NEC and that PAF-AH and dexamethasone may prove to be beneficial in the prevention of this disease.
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